Current and ongoing progress in the therapy for resectable esophageal cancer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

There have been recent advances in the surgical approach to respectable esophageal cancer. In addition, despite the paucity of level 1 data, regardless of histology (squamous cell or adenocarcinoma), neo-adjuvant chemoradiotherapy has evolved into a de facto standard of care for resectable disease. Pathologic response rate is a surrogate for a more favorable outcome. In addition, there are a number of molecularly targeted agents that may have clinical utility for these patients. Current clinical trials have been designed with a translational research component to define which patients may benefit from the incorporation of these novel agents alongside standard combined-modality approaches.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalDiseases of the Esophagus
Volume18
Issue number4
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Adjuvant Chemoradiotherapy
Translational Medical Research
Standard of Care
Histology
Adenocarcinoma
Epithelial Cells
Clinical Trials
Therapeutics

Keywords

  • Esophageal cancer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Current and ongoing progress in the therapy for resectable esophageal cancer. / Thomas, Charles.

In: Diseases of the Esophagus, Vol. 18, No. 4, 09.2005, p. 211-214.

Research output: Contribution to journalArticle

@article{6ed70fc11eba4e53a5b2c564dab5550d,
title = "Current and ongoing progress in the therapy for resectable esophageal cancer",
abstract = "There have been recent advances in the surgical approach to respectable esophageal cancer. In addition, despite the paucity of level 1 data, regardless of histology (squamous cell or adenocarcinoma), neo-adjuvant chemoradiotherapy has evolved into a de facto standard of care for resectable disease. Pathologic response rate is a surrogate for a more favorable outcome. In addition, there are a number of molecularly targeted agents that may have clinical utility for these patients. Current clinical trials have been designed with a translational research component to define which patients may benefit from the incorporation of these novel agents alongside standard combined-modality approaches.",
keywords = "Esophageal cancer",
author = "Charles Thomas",
year = "2005",
month = "9",
doi = "10.1111/j.1442-2050.2005.00496.x",
language = "English (US)",
volume = "18",
pages = "211--214",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Current and ongoing progress in the therapy for resectable esophageal cancer

AU - Thomas, Charles

PY - 2005/9

Y1 - 2005/9

N2 - There have been recent advances in the surgical approach to respectable esophageal cancer. In addition, despite the paucity of level 1 data, regardless of histology (squamous cell or adenocarcinoma), neo-adjuvant chemoradiotherapy has evolved into a de facto standard of care for resectable disease. Pathologic response rate is a surrogate for a more favorable outcome. In addition, there are a number of molecularly targeted agents that may have clinical utility for these patients. Current clinical trials have been designed with a translational research component to define which patients may benefit from the incorporation of these novel agents alongside standard combined-modality approaches.

AB - There have been recent advances in the surgical approach to respectable esophageal cancer. In addition, despite the paucity of level 1 data, regardless of histology (squamous cell or adenocarcinoma), neo-adjuvant chemoradiotherapy has evolved into a de facto standard of care for resectable disease. Pathologic response rate is a surrogate for a more favorable outcome. In addition, there are a number of molecularly targeted agents that may have clinical utility for these patients. Current clinical trials have been designed with a translational research component to define which patients may benefit from the incorporation of these novel agents alongside standard combined-modality approaches.

KW - Esophageal cancer

UR - http://www.scopus.com/inward/record.url?scp=33644796262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644796262&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2050.2005.00496.x

DO - 10.1111/j.1442-2050.2005.00496.x

M3 - Article

C2 - 16128775

AN - SCOPUS:33644796262

VL - 18

SP - 211

EP - 214

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 4

ER -